Kathryn Stackhouse

Kathryn Stackhouse

Auto-generated profile, based on publicly available information

Kathryn Stackhouse

Department of Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
CWChase J Wehre
Chase J Wehre
RRRoma Raj
Roma Raj
NANihal Aykun
Nihal Aykun
DODanny Orabi
Danny Orabi
KSKathryn Stackhouse
Kathryn Stackhouse
FAFederico Aucejo
Federico Aucejo
PURPOSE: Liver metastases occur in about 50% of colorectal cancer cases and drive patient outcomes. Circulating tumor DNA (ctDNA) is emerging as a diagnostic, surveillance, and tumor mutational information tool. METHODS: Patients with colorectal cancer liver metastasis (CCLM) seen in a multidisciplinary liver tumor clinic from January to August 2022 received ctDNA testing on each visit. ctDNA was obtained using the Guardant360 platform. Tumor mutational burden (TMB) is defined as the number of identified mutations per megabase of genome analyzed. RESULTS: Fifty-two patients had available ctDNA, with 34 (65%) tested preoperatively and 18 (35%) postoperatively; nine patients had sequential pre- and postoperative testing. The median time to test result was 12 days (IQR, 10-13.5). There were a greater number of somatic mutations identified preoperatively (n = 29 v n = 11) and a greater genomic heterogeneity ( P = .0069). The mean TMB score was 12.77 in those without pathologic response to cytotoxic therapy and 6.0 in those with pathologic response ( P = .10). All nine patients with sequential testing were positive preoperatively, compared with just three (33.3%) postoperatively ( P = .0090). Positive postoperative ctDNA was associated with the increased likelihood of disease recurrence after resection (57%) versus negative ctDNA (0%, P = .0419). CONCLUSION: Routine ctDNA screening in patients with CCLM is logistically feasible. Liver resection and/or transplant may be associated with clearance of detectable ctDNA and a reduction in TMB or genomic heterogeneity. Persistence of ctDNA alterations postresection appears predictive of disease recurrence. Further studies are necessary to confirm these findings, and longitudinal ctDNA testing is needed to monitor changing tumor biology.

29 April 2023 in HPB
Verified
Journal Article
Closed access
CWChase J Wehre
Chase J Wehre
KSKathryn A. Stackhouse
Kathryn A. Stackhouse
JCJenny Chang
Jenny Chang
MHMir S. Hossain
Mir S. Hossain
JMJohn McMichael
John McMichael
RWR. Matthew Walsh
R. Matthew Walsh

1 November 2019 in HPB
Verified
Journal Article
Closed access
AOAna Sofia Ore
Ana Sofia Ore
SKSjors Klompmaker
Sjors Klompmaker
KSKathryn Stackhouse
Kathryn Stackhouse
MSMonica Solis-Velasco
Monica Solis-Velasco
MFMichiel Francken
Michiel Francken
AMA. James Moser
A. James Moser

12 June 2023 in HPB
Verified
Journal Article
Closed access
JCJenny H. Chang
Jenny H. Chang
MHMir S. Hossain
Mir S. Hossain
KSKathryn Stackhouse
Kathryn Stackhouse
FDFadi Dahdaleh
Fadi Dahdaleh
JDJason Denbo
Jason Denbo
SNSamer Naffouje
Samer Naffouje

1 March 2012 in JACC
Verified
Journal Article
Closed access
KSKathryn Stackhouse
Kathryn Stackhouse
SGSachin Goel
Sachin Goel
AQAthar Qureshi
Athar Qureshi
SKSamir Kapadia
Samir Kapadia
LPLourdes Prieto
Lourdes Prieto
RKRichard Krasuski
Richard Krasuski

22 May 2025 in Annals of Surgery
Verified
Journal Article
Closed access
SNSamer A. Naffouje
Samer A. Naffouje
TAToms Augustin
Toms Augustin
RSRobert Simon
Robert Simon
DJDaniel Joyce
Daniel Joyce
RNRobert Do Naples
Robert Do Naples
FDFadi S. Dahdaleh
Fadi S. Dahdaleh
An abstract is unavailable. This article is available as a PDF only.